alogliptin benzoate + metformin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
alogliptin benzoate + metformin: clinical details
Prescribing considerations
- Licensed only for adults with type 2 diabetes; not for type 1 diabetes or as an insulin substitute.
- Review renal function, dehydration risk, alcohol use, cardiorespiratory hypoxia, pancreatitis history and previous serious DPP-4-inhibitor hypersensitivity.
- Arrange appropriate interruption around iodinated contrast procedures and surgery involving general, spinal or epidural anaesthesia.
Contraindications and cautions
- Hypersensitivity to either active ingredient, an excipient or a previous serious reaction to any DPP-4 inhibitor
- Acute metabolic acidosis, including lactic acidosis or diabetic ketoacidosis, and diabetic pre-coma
- Severe renal failure
- Acute illness likely to impair renal function, including dehydration, severe infection or shock
- Hepatic impairment
- Acute alcohol intoxication or alcoholism
Monitoring
- Assess renal function before treatment and regularly thereafter.
- Monitor glycaemic response and watch for hypoglycaemia when insulin or pioglitazone is also used.
- Check vitamin B12 if deficiency symptoms occur.
- Promptly assess persistent severe abdominal pain for pancreatitis and symptoms suggestive of hepatic injury.
Clinical pharmacology
Alogliptin selectively inhibits DPP-4, increasing active GLP-1 and GIP. Metformin reduces hepatic glucose production and improves peripheral insulin sensitivity. Both components are substantially eliminated through the kidneys.
Formulation and product differences
- The selected product is a fixed-combination film-coated tablet containing alogliptin benzoate and metformin hydrochloride.
- If fixed combinations cannot provide suitable component adjustment, separate alogliptin and metformin products are required.
alogliptin benzoate + metformin preparations and strengths
Tablet
Route: Oral
Strengths: 12.5 mg + 1000 mg
alogliptin benzoate + metformin interactions
Tell the prescriber, pharmacist and imaging or surgical team about this combination.
Insulin or pioglitazone
Combining these increases the likelihood of hypoglycaemia and requires clinical review and monitoring.
Iodinated contrast media
Contrast-related kidney injury can cause metformin accumulation; the clinical team must manage temporary interruption and check renal function.
NSAIDs, ACE inhibitors, angiotensin receptor blockers and diuretics
These can impair renal function and increase the risk of metformin-associated lactic acidosis, particularly during acute illness or dehydration.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.